In SLE, anti-TRIM21 antibodies inhibit the degradation of IRF, leading to an imbalance in IFN expression and an increase in TRIM21 expression; however, this is not the case in anti-TRIM21 antibodies negative populations, suggesting that anti-TRIM21 antibodies are involved in the progression of anti-TRIM21 positive SLE by interfering with the ubiquitination and degradation of IRF by TRIM21 (149). This evidence concerns the gene TRIM21 and systemic lupus erythematosus.